---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004231"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:03:59.603760+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mirum reports $76M total rev in 2022; LIVMARLI net sales $74M; CFO Clements to step down

## Summary
- Total revenue $76M, LIVMARLI net product sales $74M for full year 2022 (preliminary unaudited).
- Q4 2022 product sales $27M including $5M international partner orders.
- CFO Ian Clements to step down effective May 15, 2023; will serve as consultant for 12 months.
- sNDA for LIVMARLI in PFIC on track for Q1 2023; multiple pipeline catalysts in 2023.
- Cash and investments ~$252M as of Dec 31, 2022.

## SEC filing metadata
- accession: 0001193125-23-004231
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/d380757d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004231
- JSON: https://secwatch.observer/filing/0001193125-23-004231.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004231.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported 2022 results: revenue $76 million total revenue.
  - Period: 2022
  - Revenue: $76 million total revenue
  - Result: preliminary results
  source text: $76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported Fourth quarter 2022 results: revenue $27 million estimated product sales.
  - Period: Fourth quarter 2022
  - Revenue: $27 million estimated product sales
  - Result: preliminary results
  source text: Fourth quarter 2022 estimated product sales of $27 million includes an estimated $5 million of international sales through partner market supply orders, including inventory;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm
- Executive change
  Ian Clements departed as Chief Financial Officer at Mirum Pharmaceuticals, Inc..
  - Action: resign
  - Role: Chief Financial Officer
  source text: Dr. Clements will resign as Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523004231/0001193125-23-004231-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.